- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00336518
Continuing Treatment With Pegasys and Copegus
Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24
Primary objective is to measure sustained viral response given to continuation or prolongation of combined Pegasys&Copegus treatment
Secondary objective is to measure histological response given to continuation or prolongation of combined Pegasys&Copegus treatment measured by non-invasive methods
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prospective, multicentre, randomized, open-label comparative study
According to our national guideline of management of patient with chronic viral hepatitis, patients need to stop therapy if they do not achieve response.
These patients can enter to the study at two time points:
- at week 16, if HCV RNS PCR measured at week 12 is positive and serum ALT > 1ULN, but decreased
- at week 28, if HCV RNS PCR measured at week 24 is still positive, but serum ALT < 2ULN.
Patients are randomized to one of the following arms:
- S (standard) group: Pegasys&Copegus combined therapy 180 mcg/week & weight/based 1000-1200 mg/day for a total of 48 weeks of treatment
- P (prolonged) group: Pegasys&Copegus combined therapy 180 mcg/week & -weight/based 1000-1200 mg/day for a total of 72 weeks of treatment.
After completing treatment period patients enter into a 24-week follow up.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: János Schuller, Dr.
- Phone Number: +36 1 455-8127
Study Contact Backup
- Name: Edit Villert
- Phone Number: +36 1 455-8127
Study Locations
-
-
-
Budapest, Hungary, 1097
- Recruiting
- Szt. László Hospital
-
Contact:
- János Schuller, Dr.
- Phone Number: +36 1 455-8228
-
Contact:
- Edit Villert
- Phone Number: +36 1 455-8228
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male and female patients above 18 and below 65 years of age chronically infected with genotype 1 HCV receiving combined Pegasys&Copegus treatment first time in-line with the valid treatment guideline approved by the National Interferon Committee (see attached guideline)
Subgroup 1:
- Positive HCV PCR result at week 12 of the ongoing treatment
- ALT > 1ULN, but the value decreased by week 12
Subgroup 2:
- ALT was normal and PCR was positive at week 12, therefore combined treatment could be continued between week 12 and 24 based on the approved guideline
- Positive HCV RNA PCR at week 24 of the ongoing treatment
- GPT < 2 ULN at week 24 of the ongoing treatment.
Exclusion Criteria:
- Women with ongoing pregnancy or breast feeding
- Therapy with any systemic anti-neoplastic or immunomodulatory treatment at inclusion or within 6 months prior to it
- Any investigational drug usage at inclusion or within 6 weeks prior to it
- Co/infection with hepatitis A, B or HIV
- Any chronic liver disease other than HCV infection
- Sign or symptom of hepatocellular carcinoma
- Decompensated liver disease
- History of depression or any other relevant psychiatric disease which, in the opinion of a psychiatrist or neurologist, contraindicates study therapy
- Uncontrolled thyroid dysfunction
- Severe retinopathy
- Evidence of regular alcohol consumption at inclusion or within 1 year prior to it
- Any side effect probably caused by ongoing combined treatment which, in the opinion of the investigator, contraindicates continuation of the therapy or necessitates dose reduction of any drug in the combination therapy
- Unwillingness to provide informed consent
Subgroup 1:
Laboratory findings at week 16 of the ongoing combined Pegasys&Copegus treatment:
- ANC <1000/mm3
- PLT <75.000/mm3
- hemoglobin <10g/dl
- creatinine >1,5 ULN
Subgroup 2:
Laboratory findings at week 28 of the ongoing combined Pegasys&Copegus treatment:
- ANC <1000/mm3
- PLT <75.000/mm3
- hemoglobin <10g/dl
- creatinine >1,5 ULN
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Sustained viral response given to continuation or prolongation of combined Pegasys&Copegus treatment
|
Secondary Outcome Measures
Outcome Measure |
---|
Histological response given to continuation or prolongation of combined Pegasys&Copegus treatment measured by non-invasive methods
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: János Schuller, Dr., Májbetegekért Alapítvány
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis, Chronic
- Hepatitis
- Hepatitis C
- Hepatitis C, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Ribavirin
- Peginterferon alfa-2a
Other Study ID Numbers
- MBA 1/2005
- ML 20142
- EuDract: 2005-004531-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis C
-
Sohag UniversityRecruiting
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical University; Yamanashi...Recruiting
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis cChina
-
Ascletis Pharmaceuticals Co., Ltd.CompletedChronic Hepatitis cChina
-
Hospices Civils de LyonCompleted
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
Clinical Trials on ribavirin
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
University of Roma La SapienzaCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Hoffmann-La RocheCompletedHealthy VolunteerMexico
-
University of BernRoche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaboratorsCompleted
-
Janssen-Cilag International NVNo longer availableHepatitis CAustralia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
-
Conatus Pharmaceuticals Inc.Completed
-
National Institute of Diabetes and Digestive and...CompletedHepatitis C, ChronicUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedHEAD & NECK CancerUnited States
-
Kaohsiung Medical University Chung-Ho Memorial...Completed